Related Experiment Video

Updated: Sep 5, 2025

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
07:30

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

Published on: April 23, 2021

3.1K

The Intersection of SGLT2 Inhibitors, Cognitive Impairment, and CKD

J Ariana Noel1,2, Ingrid Hougen1,2, Manish M Sood1

  • 1Department of Nephrology, The Ottawa Hospital, Ottawa, ON, Canada.

Frontiers in Neurology
|July 8, 2022
PubMed

Insights

Cognitive impairment (CI) in chronic kidney disease (CKD) may be preventable by managing vascular risk factors. Sodium glucose transport protein 2 inhibitors (SGLT2i) show potential for disease modification in CKD patients with CI.

Area of Science:

  • Nephrology
  • Neurology
  • Cardiology

Background:

  • Cognitive impairment (CI) and declining kidney function are common in aging individuals with chronic kidney disease (CKD).
  • Vascular disease burden, driven by comorbidities like hypertension, diabetes, and cardiovascular disease, contributes to CI in CKD.
  • Managing vascular risk factors may indirectly prevent CI in CKD patients.

Purpose of the Study:

  • To explore the hypothesis that Sodium-Glucose Transport Protein 2 inhibitors (SGLT2i) possess disease-modifying properties for CI in individuals with CKD.
  • To review emerging evidence on the role of SGLT2i in managing cognitive health within the context of CKD.

Main Methods:

  • This is a narrative review.
  • Examination of existing literature on SGLT2i, CKD, and cognitive impairment.
  • Synthesis of evidence regarding the potential impact of SGLT2i on vascular risk and cognitive function.

Main Results:

  • SGLT2i are becoming a standard treatment for CKD, type 2 diabetes, and heart failure.
  • Emerging evidence suggests SGLT2i may influence vascular health, a key factor in CI.
  • The potential disease-modifying effects of SGLT2i on CI in CKD warrant further investigation.

Conclusions:

  • SGLT2i represent a promising therapeutic avenue for potentially mitigating CI in CKD patients.
  • Further research is needed to confirm the direct impact of SGLT2i on cognitive function in CKD.
  • The interplay between SGLT2i, kidney function, and cognitive health is an active area of investigation.

Keywords:
SGLT2 inhibitoralbuminuriachronic kidney diseasecognitive impairmentdementia

More Related Videos

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid06:21

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

1.6K
Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

10.4K

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
76
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
80
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
64
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
154
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
56
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
206